Entity

Time filter

Source Type

EAGAN, MN, United States

Patent
Biothera | Date: 2012-09-07

The invention generally relates to soluble beta-glucan compositions and method of using such compositions. In one aspect, an adjuvant for a pharmaceutical composition is described which includes a soluble beta-glucan and a TLR agonist, each in an amount that, in combination with the other, is effective to increase a subjects immune response to an antigen. In another aspect, compositions that generally include an antigen component, a soluble beta-glucan component, and a TLR agonist component and a method that generally includes administering to a subject a composition that comprises a soluble beta-glucan and a TLR agonist, each in an amount that, in combination with the other, is effective to increase a subjects immune response to an antigen, are described.


Grossman W.,Biothera
Human vaccines & immunotherapeutics | Year: 2013

It's the question that every grade school kid has to answer at some point or another--"What do you want to be when you grow up?" My mom still has the second grade paper on which I first wrote down that I wanted to be a "physician scientist." I'm quite certain that I probably didn't know exactly what a physician scientist was at the time. I certainly didn't know any physician scientists personally, nor was I exposed to academic environments in the tiny Minnesota town in which I grew up. All I'm certain of, was at that time, I liked reading about science. Unfortunately, I soon came to know the medical profession all too personally. Source


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 149.45K | Year: 2014

DESCRIPTION (provided by applicant): Fungal infections, particularly in immunocompromised patients, are a serious and growing problem. Although antifungal therapeutics have improved greatly, failures and relapse are common. Aspergillus fumigatus is a primary cause of these infections in several patient populations: transplants, leukemics, genetic deficiencies such as chronic granulomatous disease and others, with mortality remaining high. Preventative antifungal vaccines are an attractive, but as yet unrealized, option. The goal of this proposal is to develop a prototype glucan-protein vaccine by conjugating a protein to a particulate -glucan immunomodulator (i.e., WGP), a cell wall component of many pathogenic fungi. Preliminary work using WGP alone or conjugated to a non-specific protein, bovine serum albumin (BSA), indicated that a glucan-protein vaccine was active against Aspergillus and Coccidioides. The work described in this proposal will examine the potential of conjugating a specific, immunodom


Patent
Biothera | Date: 2010-07-22

Methods relating to treating conditions that do not respond well to EGF-r antagonist therapies are disclosed. Generally, the methods include administering to a subject a composition that includes a -glucan and, as either a second composition or a second component of the composition, either antibody that binds to at least one antigen specific to the KRAS-mutated cells and/or an EGF-r antagonist.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 159.14K | Year: 2010

Pancreatic cancer is a "rare" and fata l disease, with few treatment options. Currently, promising antitumor strategies utilize combination therapies, with each agent targeting separate aspects of oncogenesis. Disappointingly, combination of anti- EGFR monoclonal antibody (MAb), cetuximab, with standard-of-care, gemcitabine, failed to improve survival in this disease. Although EGFR is over-expressed in >90% of pancreatic carcinomas -90% also contain KRAS mutations. We herein propose a strategy that could overcome resistance of KRAS mutations to anti-EGFR MAbs. Biothera is developing Imprime-PGG¿, a beta 1,3/1,6 glucose polymer, as an adjunct to MAbs for cancer treatment. The proprietary agent, Imprime, induces neutrophil-mediated cellular cytotoxicity, where Imprime 'primes' neutrophils (comprise -50%-70% of human immune cells) to recognize and kill MAb targeted tumors. Preclinically, Imprime has shown therapeutic efficacy as an adjunct to MAbs in various tumor models, including KRAS-mutated lung and colon carcinoma models. This coupled wi th the safety and recent efficacy data from a Phase 1 b/2 metastatic CRC study supports Imprime to be a safe and effective drug. Overall objective is to establish preclinical proof of concept for this novel treatment approach in pancreatic cancer xenografts

Discover hidden collaborations